More News

09 Jan 2020 eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types
09 Jan 2020 Kaleido Biosciences Announces Collaboration with Janssen to Explore the Potential for Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions by Promoting Healthy Function of the Gut Microbiome
09 Jan 2020 Aro Biotherapeutics and Ionis Enter Licensing and Collaboration Agreement Focused on Cell-Specific Delivery of Antisense Oligonucleotides
09 Jan 2020 Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
09 Jan 2020 Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University
09 Jan 2020 Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.
09 Jan 2020 Bayer and Evotec form new strategic alliance focusing on polycystic ovary syndrome
09 Jan 2020 Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies
09 Jan 2020 Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline
09 Jan 2020 WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
09 Jan 2020 SAB Biotherapeutics Announces Research Collaboration With CSL Behring
08 Jan 2020 Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766
08 Jan 2020 Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV
07 Jan 2020 Cytovia Therapeutics and the University of California, San Francisco enter into a partnership to develop precision gene-edited CAR-NK cell therapy
07 Jan 2020 Galecto and PharmAkea Merge to Create Strong Clinical-Stage Company Developing First-in-Class Therapeutics in Fibrosis and Cancer
07 Jan 2020 PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration
06 Jan 2020 Yisheng Biopharma and Tavotek Biotherapeutics Announce Strategic Research Alliance for Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment
06 Jan 2020 Merck Establishes Strategic Oncology Collaboration with Taiho and Astex
06 Jan 2020 GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China
03 Jan 2020 Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing
02 Jan 2020 Arena Pharmaceuticals and Beacon Discovery Expand Strategic Relationship Focusing on Multiple Immune and Inflammatory Targets
02 Jan 2020 Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson
02 Jan 2020 Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China
30 Dec 2019 Milestone for Biopharmaceuticals in China
30 Dec 2019 Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up